脂肪酸代谢与卵巢癌

doi:10.11904/j.issn.1002-3070.2023.05.007

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (5): 429-433.doi: 10.11904/j.issn.1002-3070.2023.05.007

脂肪酸代谢与卵巢癌

樊婷婷¹, 丁丹妮¹, 赵子雪¹, 于洋² 综述, 韩凤娟² 审校

1.黑龙江中医药大学研究生院(哈尔滨 150040);
2.黑龙江中医药大学附属第一医院

收稿日期:2022-05-21 修回日期:2023-01-23 出版日期:2023-10-28 发布日期:2024-03-18
通讯作者: 韩凤娟,E-mail:hanfengjuan2004@163.com
作者简介:樊婷婷,女,(1998-),硕士研究生,从事中西医结合治疗妇科肿瘤的研究。
基金资助:
国家自然科学基金面上项目(编号:82074484)

Fatty acid metabolism and ovarian cancer

FAN Tingting¹, DING Danni¹, ZHAO Zixue¹, YU Yang², HAN Fengjuan²

1. Graduate School,Heilongjiang University of Traditional Chinese Medicine,Harbin 150040,China;
2. The First Affiliated Hospital,Heilongjiang University of Traditional Chinese Medicine

Received:2022-05-21 Revised:2023-01-23 Online:2023-10-28 Published:2024-03-18

摘要/Abstract

摘要： 卵巢癌是女性生殖系统中常见的恶性肿瘤,其发病和调控机制极其复杂,至今尚不明确。脂肪酸代谢主要涵盖脂肪酸摄取、合成、氧化过程。既往研究表明,脂肪酸代谢在卵巢癌的发生发展中发挥独特的作用,因此本综述回顾了现有文献,深入探讨脂肪酸代谢与卵巢癌之间的相关性,旨在为卵巢癌的脂肪酸代谢机制和靶向治疗提供新的视角和思考。

关键词: 卵巢癌, 脂肪酸代谢, 酶, 靶向治疗

Abstract: Ovarian cancer is a common malignant tumor in the female reproductive system, and its pathogenesis and regulatory mechanisms are extremely complex and still unclear. Fatty acid metabolism mainly involves the processes of fatty acid uptake, synthesis, and oxidation. Previous studies have shown that fatty acid metabolism plays a unique role in the occurrence and development of ovarian cancer. Therefore, this article reviews existing literature and delves into the correlation between fatty acid metabolism and ovarian cancer, aiming to provide new perspectives and reflections on the mechanism of fatty acid metabolism and targeted treatment of ovarian cancer.

Key words: Ovarian cancer, Fatty acid metabolism, Enzymes, Targeted therapy

中图分类号:

R737.31

樊婷婷, 丁丹妮, 赵子雪, 于洋, 韩凤娟. 脂肪酸代谢与卵巢癌[J]. 实用肿瘤学杂志, 2023, 37(5): 429-433.

FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer[J]. Journal of Practical Oncology, 2023, 37(5): 429-433.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/429

参考文献

1 Kong BH,Liu JH,Huang H,et al.Clinical application guidelines for PARP inhibitors in ovarian cancer(2022 Edition)[J].Progress in Obstetrics and Gynecology,2022,31(8):561-572.
2 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021 May;71(3):209-249.
3 Huang X,Feng B,Liu M,et al.Preclinical detection of lysophosphatidic acid:A new window for ovarian cancer diagnostics[J].Talanta,2022,247:123561.
4 Koundouros N,Poulogiannis G.Reprogramming of fatty acid metabolism in cancer[J].Br J Cancer,2020,122(1):4-22.
5 Chen YJ,Liao WX,Huang SZ,et al.Prognostic and immunological role of CD36:A pan-cancer analysis[J].J Cancer,2021,12(16):4762-4773.
6 Pascual G,Avgustinova A,Mejetta S,et al.Targeting metastasis-initiating cells through the fatty acid receptor CD36[J].Nature,2017,541(7635):41-45.
7 Gharpure KM,Pradeep S,Sans M,et al.FABP4 as a key determinant of metastatic potential of ovarian cancer[J].Nat Commun,2018,9:2923.
8 Granchi C.ATP citrate lyase(ACLY)inhibitors:An anti-cancer strategy at the crossroads of glucose and lipid metabolism[J].Eur J Med Chem,2018,157:1276-1291.
9 Wang Y,Wang Y,Shen L,et al.Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer[J].Oncol Rep,2012,27(4):1156-1162.
10 Bauerschlag DO,Maass N,Leonhardt P,et al.Fatty acid synthase overexpression:target for therapy and reversal of chemoresistance in ovarian cancer[J].J Transl Med,2015,13:146.
11 Jiang L,Fang X,Wang H,et al.Ovarian cancer-Intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells[J].Front Immunol,2018,9:2927.
12 Ji Z,Shen Y,Feng X,et al.Deregulation of lipid metabolism:The critical factors in ovarian cancer[J].Front Oncol,2020,10:593017.
13 Xuan Y,Wang H,Yung MM,et al.SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells[J].Theranostics,2022,12(7):3534-3552.
14 Tesfay L,Paul BT,Konstorum A,et al.Steroyl-CoA Desaturase 1(SCD1)protects ovarian cancer cells from ferroptotic cell death[J].Cancer Res,2019,79(20):5355-5366.
15 Luis G,Godfroid A,Nishiumi S,et al.Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1(SCD1)in cancer cells and Fatty Acid Biding Protein-4(FABP4)in tumor microenvironment promote tumor recurrence[J].Redox Biol,2021,43:102006.
16 Sawyer BT,Qamar L,Yamamoto TM,et al.Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression[J].Mol Cancer Res,2020,18(7):1088-1098.
17 Yang H,Zhao H,Ren Z,et al.Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC[J].Acta Biochim Biophys Sin,2022,54(2):220-231.
18 Icard P,Wu Z,Fournel L,et al.ATP citrate lyase:A central metabolic enzyme in cancer[J].Cancer Lett,2020,471:125-134.
19 Falchook G,Infante J,Arkenau HT,et al.First-in-human study of the safety,pharmacokinetics,and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors[J].EClinicalMedicine,2021,34:100797.
20 Grunt TW,Slany A,Semkova M,et al.Membrane disruption,but not metabolic rewiring,is the key mechanism of anticancer-action of FASN-inhibitors:a multi-omics analysis in ovarian cancer[J].Sci Rep,2020,10(1):14877.
21 Tesfay L,Paul BT,Konstorum A,et al.Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death[J].Cancer Res,2019,79(20):5355-5366.
22 Liu Y,Liu X,Wang H,et al.Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells[J].Phytomedicine,2022,101:154102.
23 Jin HR,Wang J,Wang ZJ,et al.Lipid metabolic reprogramming in tumor microenvironment:from mechanisms to therapeutics[J].J Hematol Oncol,2023,16:103.
24 Reyes-Castellanos G,Abdel Hadi N,Gallardo-Arriaga S,et al.Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression in vivo[J].iScience,2023,26(6):106899.

[1]	高燕, 姚盟成, 李哲丰, 韩晓阳, 岳文涛. 单细胞测序数据揭示DMKN在卵巢癌中的诊断及预测价值[J]. 实用肿瘤学杂志, 2023, 37(6): 478-484.
[2]	付鑫雅, 胡灵丹, 张志坚, 马秀梅. HPA通过上调MCP-1/CCR2促进胃癌发生侵袭和转移[J]. 实用肿瘤学杂志, 2023, 37(4): 329-336.
[3]	苗玲, 赵之寒, 王敏. 非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义[J]. 实用肿瘤学杂志, 2023, 37(4): 344-350.
[4]	隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.
[5]	伦立鑫, 钟振滨, 赵新宇, 吴筹, 郝春成. 抗EGFR治疗在头颈部鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 276-280.
[6]	曾平, 郭鹏翔, 骆横. 人端粒酶逆转录酶在肿瘤转录调控机制中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 68-72.
[7]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[8]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[9]	赵雅茹, 武云. 胃癌常见生物标记物及相应靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 483-488.
[10]	温晓星, 刘大海, 吴学辉, 王炳平, 房涛. 敲减骨桥蛋白对吉非替尼耐药的非小细胞肺癌PC9细胞凋亡的研究[J]. 实用肿瘤学杂志, 2022, 36(4): 310-315.
[11]	孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.
[12]	郑艳丽, 贺建霞. 弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 259-262.
[13]	杨楠, 王棹, 张玉, 张云艳. SMYD2在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 273-277.
[14]	陈素, 隋红. 抗HER2治疗在转移性结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 288-292.
[15]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.

脂肪酸代谢与卵巢癌

Fatty acid metabolism and ovarian cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价